193 related articles for article (PubMed ID: 34976591)
1. Development of CD44E/s dual-targeting DNA aptamer as nanoprobe to deliver treatment in hepatocellular carcinoma.
Lo CW; Chan CKW; Yu J; He M; Choi CHJ; Lau JYW; Wong N
Nanotheranostics; 2022; 6(2):161-174. PubMed ID: 34976591
[No Abstract] [Full Text] [Related]
2. Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells.
Alshaer W; Hillaireau H; Vergnaud J; Ismail S; Fattal E
Bioconjug Chem; 2015 Jul; 26(7):1307-13. PubMed ID: 25343502
[TBL] [Abstract][Full Text] [Related]
3. Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway.
Hou H; Ge C; Sun H; Li H; Li J; Tian H
Cancer Sci; 2018 Apr; 109(4):1088-1100. PubMed ID: 29377347
[TBL] [Abstract][Full Text] [Related]
4. Selection and Characterization of a Novel DNA Aptamer, Apt-07S Specific to Hepatocellular Carcinoma Cells.
Yu XX; Ge KL; Liu N; Zhang JY; Xue ML; Ge YL
Drug Des Devel Ther; 2020; 14():1535-1545. PubMed ID: 32368012
[TBL] [Abstract][Full Text] [Related]
5. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
[TBL] [Abstract][Full Text] [Related]
6. Selection of an aptamer against mouse GP2 by SELEX.
Hanazato M; Nakato G; Nishikawa F; Hase K; Nishikawa S; Ohno H
Cell Struct Funct; 2014; 39(1):23-9. PubMed ID: 24334484
[TBL] [Abstract][Full Text] [Related]
7. In vitro selection of modified RNA aptamers against CD44 cancer stem cell marker.
Ababneh N; Alshaer W; Allozi O; Mahafzah A; El-Khateeb M; Hillaireau H; Noiray M; Fattal E; Ismail S
Nucleic Acid Ther; 2013 Dec; 23(6):401-7. PubMed ID: 24171482
[TBL] [Abstract][Full Text] [Related]
8. Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers.
Rong Y; Chen H; Zhou XF; Yin CQ; Wang BC; Peng CW; Liu SP; Wang FB
Oncotarget; 2016 Feb; 7(7):8282-94. PubMed ID: 26882565
[TBL] [Abstract][Full Text] [Related]
9. Screening and verification of ssDNA aptamers targeting human hepatocellular carcinoma.
Lu B; Wang J; Zhang J; Zhang X; Yang D; Wu L; Luo Z; Ma Y; Zhang Q; Ma Y; Pei X; Yu H; Liu J
Acta Biochim Biophys Sin (Shanghai); 2014 Feb; 46(2):128-35. PubMed ID: 24300391
[TBL] [Abstract][Full Text] [Related]
10. Recognition and capture of metastatic hepatocellular carcinoma cells using aptamer-conjugated quantum dots and magnetic particles.
Wang FB; Rong Y; Fang M; Yuan JP; Peng CW; Liu SP; Li Y
Biomaterials; 2013 May; 34(15):3816-27. PubMed ID: 23465488
[TBL] [Abstract][Full Text] [Related]
11. Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas.
Sett A; Borthakur BB; Bora U
Clin Transl Oncol; 2017 Aug; 19(8):976-988. PubMed ID: 28224267
[TBL] [Abstract][Full Text] [Related]
12. Development of a DNA Aptamer against Multidrug-Resistant Hepatocellular Carcinoma for
Zhang L; Zhou L; Zhang H; Zhang Y; Li L; Xie T; Chen Y; Li X; Ling N; Dai J; Sun X; Liu J; Zhao J; Peng T; Ye M
ACS Appl Mater Interfaces; 2021 Nov; 13(46):54656-54664. PubMed ID: 34779207
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer.
Park JY; Chae JR; Cho YL; Kim Y; Lee D; Lee JK; Kang WJ
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33080969
[TBL] [Abstract][Full Text] [Related]
14. Induction of tumor initiation is dependent on CD44s in c-Met⁺ hepatocellular carcinoma.
Dang H; Steinway SN; Ding W; Rountree CB
BMC Cancer; 2015 Mar; 15():161. PubMed ID: 25886575
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44.
Somasunderam A; Thiviyanathan V; Tanaka T; Li X; Neerathilingam M; Lokesh GL; Mann A; Peng Y; Ferrari M; Klostergaard J; Gorenstein DG
Biochemistry; 2010 Oct; 49(42):9106-12. PubMed ID: 20843027
[TBL] [Abstract][Full Text] [Related]
16. A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy.
Zhang L; Wang M; Zhu Z; Ding C; Chen S; Wu H; Yang Y; Che F; Li Q; Li H
Int J Nanomedicine; 2021; 16():3217-3240. PubMed ID: 34007175
[TBL] [Abstract][Full Text] [Related]
17. Standard CD44 modulates YAP1 through a positive feedback loop in hepatocellular carcinoma.
Fan Z; Xia H; Xu H; Ma J; Zhou S; Hou W; Tang Q; Gong Q; Nie Y; Bi F
Biomed Pharmacother; 2018 Jul; 103():147-156. PubMed ID: 29649630
[TBL] [Abstract][Full Text] [Related]
18. CD44: structure, function, and association with the malignant process.
Naor D; Sionov RV; Ish-Shalom D
Adv Cancer Res; 1997; 71():241-319. PubMed ID: 9111868
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner.
Phillips RJ; Helbig KJ; Van der Hoek KH; Seth D; Beard MR
World J Gastroenterol; 2012 Jul; 18(26):3389-99. PubMed ID: 22807608
[TBL] [Abstract][Full Text] [Related]
20. Regulation of human CD44H and CD44E isoform binding to hyaluronan by phorbol myristate acetate and anti-CD44 monoclonal and polyclonal antibodies.
Liao HX; Levesque MC; Patton K; Bergamo B; Jones D; Moody MA; Telen MJ; Haynes BF
J Immunol; 1993 Dec; 151(11):6490-9. PubMed ID: 7504022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
